#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant

This article discusses a clinical trial investigating the long-term safety and effectiveness of FLT201, an innovative gene therapy treatment for Gaucher Disease Type 1. FLT201 is an adeno-associated viral vector containing a modified gene that produces an enzyme crucial for managing the disease. The study, known as GALILEO-2, aims to assess the safety, durability, and various effects of this treatment on patients who have previously received FLT201.

Table of Contents

What is FLT201?

FLT201 is a new type of medicine being studied for the treatment of Gaucher Disease Type 1. It’s what doctors call a gene therapy, which means it aims to treat a disease by introducing genetic material into a person’s cells[1].

The full name of FLT201 is quite complex: “Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant.” It’s also known by other names like “Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human β-glucocerebrosidase variant”[1].

How Does FLT201 Work?

FLT201 works by using a harmless virus (called an adeno-associated virus) to deliver a healthy version of a gene to cells in the body. This gene contains instructions for making an enzyme called glucocerebrosidase (also known as GCase)[1].

In people with Gaucher Disease Type 1, this enzyme doesn’t work properly. By providing cells with the correct instructions to make this enzyme, FLT201 aims to help the body break down certain fatty substances that otherwise build up and cause problems[1].

What is Gaucher Disease Type 1?

Gaucher Disease Type 1 is a rare genetic disorder. People with this condition lack enough of the enzyme glucocerebrosidase. This leads to a buildup of fatty substances in various organs, particularly the spleen, liver, and bone marrow. This can cause a range of symptoms, including an enlarged spleen and liver, low blood counts, and bone problems[1].

Clinical Trial Objectives

A clinical trial called GALILEO-2 is being conducted to study FLT201. The main goals of this trial are:

  1. To assess the long-term safety of FLT201 in people with Gaucher Disease Type 1[1].
  2. To see how long the effects of FLT201 last, particularly how long it continues to help the body produce the GCase enzyme[1].
  3. To investigate how well FLT201 helps clear a substance called glucosylsphingosine (lyso-Gb1) from the body[1].
  4. To assess how FLT201 affects important health markers like hemoglobin levels, platelet count, and the size of the spleen and liver[1].
  5. To study the body’s immune response to FLT201[1].

Who Can Participate in the Trial?

The trial is open to:

  • People who have previously received FLT201. This includes those who may have needed to restart or begin enzyme replacement therapy (ERT) or substrate reduction therapy (SRT)[1].
  • Participants who can give informed consent and are able to follow all the requirements of the trial[1].

What Will Be Measured in the Trial?

The researchers will be looking at several things during the trial:

  1. Any side effects that occur after receiving FLT201[1].
  2. Changes in vital signs, ECG results, physical examination findings, and laboratory test results[1].
  3. Changes in the activity and amount of the GCase enzyme in the blood over time[1].
  4. Changes in the level of a substance called lyso-Gb1 in the body[1].
  5. Changes in hemoglobin levels, platelet count, and the size of the spleen and liver (measured by MRI)[1].
  6. The body’s immune response to FLT201[1].
  7. How long it takes for the viral vector (the harmless virus used to deliver the gene) to clear from the body[1].

Potential Benefits and Risks

While FLT201 shows promise as a potential treatment for Gaucher Disease Type 1, it’s important to remember that it’s still being studied. The potential benefits could include long-lasting improvement in enzyme function and reduction in disease symptoms. However, as with any new treatment, there may be risks and side effects that are not yet fully known[1].

This trial aims to better understand both the benefits and risks of FLT201. If you have Gaucher Disease Type 1 and are interested in this trial, it’s important to discuss it with your doctor to determine if it might be appropriate for you[1].

Aspect Details
Study Name GALILEO-2
Drug Name FLT201
Condition Treated Gaucher Disease Type 1
Main Objective Assess long-term safety of FLT201
Key Secondary Objectives Investigate durability of enzyme production, assess impact on blood components and organ sizes
Eligibility Participants who have previously received FLT201
Primary Endpoint Incidence of treatment-emergent adverse events
Key Secondary Endpoints Changes in enzyme activity, blood components, organ sizes, and immune responses

FAQ

  • What is FLT201 and how does it work? FLT201 is a gene therapy treatment for Gaucher Disease Type 1. It uses an adeno-associated viral vector to deliver a modified gene that produces beta-glucocerebrosidase, an enzyme that patients with Gaucher Disease lack. This treatment aims to help the body produce the enzyme on its own, potentially reducing or eliminating the need for regular enzyme replacement therapy.
  • What is the main goal of the GALILEO-2 study? The main objective of the GALILEO-2 study is to assess the long-term safety of FLT201 in participants with Gaucher Disease Type 1 who have previously received the treatment.
  • Who can participate in this clinical trial? The trial is open to participants who have previously received FLT201 treatment, including those who may have required recommencement or initiation of enzyme replacement therapy or substrate reduction therapy. Participants must be able to give full informed consent and comply with all requirements of the trial.
  • What are some of the secondary objectives of the study? Secondary objectives include further assessing FLT201's safety, investigating the durability of enzyme production, examining the clearance of a substance called glucosylsphingosine, assessing the impact on blood components and organ sizes, and studying immune responses to the treatment.
  • How will the effectiveness of FLT201 be measured? The effectiveness will be measured through various means, including changes in enzyme activity levels, concentration of certain substances in the blood, changes in hemoglobin and platelet counts, and changes in spleen and liver volumes as measured by MRI.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant

  • Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Gaucher Disease Type 1: A genetic disorder characterized by the lack of an enzyme called glucocerebrosidase, leading to the accumulation of certain fatty substances in various organs, particularly the spleen, liver, and bone marrow.
  • Adeno-associated viral vector: A tool used in gene therapy to deliver genetic material into cells. It's derived from a virus but modified to be safe and non-infectious.
  • Beta-glucocerebrosidase (GCase): An enzyme that breaks down certain fatty substances in the body. Its deficiency causes Gaucher Disease.
  • Enzyme replacement therapy (ERT): A treatment method where the missing or deficient enzyme is regularly administered to the patient.
  • Substrate reduction therapy (SRT): A treatment approach that aims to reduce the amount of substance that the missing enzyme would normally break down.
  • Glucosylsphingosine (lyso-Gb1): A substance that accumulates in the body of patients with Gaucher Disease and is used as a biomarker to monitor the disease.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique used to visualize internal body structures.
  • Viral shedding: The release of virus particles from an infected person, which in this context is monitored to ensure safety of the gene therapy.

References

  1. http://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-flt201-for-patients-with-gaucher-disease-type-1/